ACM
ENTA icon

ADAR1 Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

ADAR1 Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$649K Buy
51,357
+10,000
+24% +$134K 0.04% 188
2025
Q4 		$652K Buy
+41,357
New +$525K 0.05% 172

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ADAR1 Capital Management's ENTA Position: Q1 2026 in Review

ADAR1 Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 24% in Q1 2026, buying an estimated $134K and bringing the position to 51,357 shares worth $649K. The position accounts for 0.04% of the portfolio, ranked #188.

ADAR1 Capital Management first reported a position in ENTA in Q4 2025 and has held it in 2 quarters since. The position peaked at $652K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • ADAR1 Capital Management held 51,357 shares of Enanta Pharmaceuticals worth $649K as of Q1 2026.
  • ADAR1 Capital Management bought 10,000 Enanta Pharmaceuticals shares in Q1 2026, an estimated $134K.
  • Enanta Pharmaceuticals made up 0.04% of ADAR1 Capital Management's portfolio in Q1 2026, its #188 holding.
  • ADAR1 Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • ADAR1 Capital Management's Enanta Pharmaceuticals position peaked at $652K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.